A Single Ascending Dose Study of HM17321 in Healthy Adult Participants

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 in healthy adult participants. The study will enroll approximately 40 healthy adults with a body mass index (BMI) of ≥20 kg/m² and ≤27 kg/m². Participants will be assigned to 1 of 5 cohorts, with each cohort consisting of 8 participants (6 receiving HM17321 and 2 receiving placebo). The total sample size may be adjusted if additional dose cohorts are added and/or existing cohorts are expanded. Participants who discontinue for reasons other than safety may be replaced at the discretion of the Sponsor and Investigator. All study drugs will be administered by subcutaneous (SC) injection into the abdominal wall. The study will include a 28-day screening period, a 5-day inpatient stay during which a single SC dose of HM17321 or placebo will be administered, and an outpatient/follow-up period through Day 29. The study duration for each participant will be approximately 8 weeks from screening to the last follow-up visit.